Objective To compare the real-word effectiveness of subcutaneous tocilizumab (TCZ-SC) and intravenous tocilizumab (TCZ-IV) in rheumatoid arthritis (RA).Methods Patients with RA with TCZ from eight ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Background: Neoadjuvant taxane, carboplatin and trastuzumab plus pertuzumab is associated with excellent treatment outcomes. The neoCARHP study aimed to evaluate the efficacy and safety of a ...

This study provides compelling evidence that SLC7A11 may serve as a potential therapeutic target for trastuzumab-resistant HER2-positive breast cancer. While the findings are well-supported by robust ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector . New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational ...

Subcutaneous (SC) formulations of anticancer agents have demonstrated advantages versus intravenous (IV) routes, including shorter administration duration, greater patient comfort and satisfaction, ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

CHICAGO — Results from the phase 3 DESTINY-Breast09 clinical trial found that the combination of trastuzumab deruxtecan (Enhertu®) with pertuzumab (Perjeta®) can delay cancer growth for longer than ...

The monoclonal antibody trastuzumab, targeting the extracellular domain of the HER2 protein, was the first targeted therapy approved in combination with chemotherapy in first-line metastatic ...

Results from the phase 2 segment of a phase 2/3 trial (NCT05980481) evaluating the antibody-drug conjugate disitamab vedotin (DV; Aidixi), PD-1 inhibitor toripalimab (Loqtorzi), and trastuzumab ...

1. ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast ...